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Pneumothorax is a rare complication in cancer chemotherapy. We report a case in which a male patient
with advanced non-small cell lung cancer (NSCLC) developed repetitive pneumothorax after receiving a
combination of the chemotherapeutic drugs geﬁtinib and amrubicin (GEF þ AMR). Both episodes of
pneumothorax occurred on the 3rd day of GEF þ AMR administration. Tube thoracostomy was per-
formed, but pulmonary air leaks persisted in the second pneumothorax. Whereas surgical intervention
was not applicable because of poor respiratory reserve, the chest tube was successfully removed by
endoscopic occlusion of bronchopleural ﬁstula with endobronchial Watanabe spigots (EWSs), a type of
silicone bronchial blocker.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Although pneumothorax is a rare complication in cancer
chemotherapy, it may be life-threatening when it occurs in patients
with extensive pulmonary involvement of cancer. Herein, we report
a case in which a lung cancer patient with extensive lung metas-
tasis experienced two episodes of pneumothorax triggered by a
speciﬁc combination of chemotherapeutic drugs. Although his 2nd
pneumothorax was complicated by sustained air leaks, it was
resolved by endobronchial occlusion with silicone bronchial
blockers.
Case presentation
A 59-year old man was urgently admitted to our hospital
because of sudden onset of dyspnea on the 3rd day of the 2nd
administration of geﬁtinib (GEF) combined with amrubicin (AMR).
Chest radiography and chest computed tomography (CT) scans
revealed left-sided pneumothorax. He had undergone a right upper(F. Imamura), okamotono@
(T. Inoue), juchidax@yahoo.
ishino), kimura-ma@mc.pref.
(T. Kumagai), okami-ji@mc.
Ltd. This is an open access article ulobectomy for lung adenocarcinoma 8 years before, but had expe-
rienced disease recurrence one year later. Treatment with geﬁtinib,
an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI), had been initiated because his lung cancer carried a
deletion in exon 19 of EGFR; this therapy had a remarkable effect.
Thereafter, he had been treated with several lines of chemotherapy
and radiation therapy for about 7 years. Further, he had undergone
pleurodesis for right malignant pleural effusion. The combination
of GEF and AMR (GEFþAMR) was initiated for the ﬁrst time in April
2014 as the 12th line treatment. Stable disease was attained with
slow decrement of the serum carcinoembryonic antigen (CEA)
value, although he had poor respiratory reserve due to cancer
spread in both lung.
After conﬁrming the presence of pneumothorax, a chest
drainage tubewas inserted into the left thoracic cavity. The left lung
was fully expanded rapidly by continuous aspiration, and the tube
was successfully removed without pleurodesis. The patient was
discharged and chemotherapy was restarted. The 3rd administra-
tion of GEF þ AMR was initiated on the 47th day from the start of
the 2nd administration. Once again, the patient was urgently
admitted to our hospital on the 3rd day of the treatment, com-
plaining of severe dyspnea. Arterial blood gas analysis revealed
severe hypoxemia and hypercapnia despite breathing 10 L/min
oxygen, indicating life-threatening hypoventilation (Table 1). Chest
CT scans revealed left-sided pneumothorax (Fig. 1). A 12 Fr chest
drainage tube was emergently inserted, and the arterial blood gasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Arterial blood gas analysis.
O2 (by mask) On admission After insertion of chest tube
10 L/min 6 L/min
pH 7.02 7.30
PaO2 (mmHg) 66.3 81.0
PaCO2 (mmHg) 100.0 45.5
HCO3 (mmol/L) 24.7 21.5
SO2 (%) 79.4 94.7
Fig. 2. Time course after the insertion of the ﬁrst EWS An EWS was inserted into the
left B5 on day 1. Because of sustained air leaks, an additional EWS was inserted into the
left B3, followed by left pleurodesis. The EWS in the left B5 was removed on day 7 to
resolve obstructive pneumonia. Since air leaks disappeared, the chest drainage tube
was removed on day14.
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a 20 Fr double lumen Trochar catheter, the air leaks continued,
resulting in collapse of the left lung when the chest tube was
clamped. Since operative intervention for pneumothorax was
inapplicable because of the patient's poor respiratory reserve,
endobronchial approach was performed (Fig. 2). Firstly, an endo-
bronchial Watanabe spigot (EWS) of 7-mm thickness was inserted
into the left B5 by using a ﬂexible bronchoscope under venous
anesthesia after determining the bronchi responsible for the air
leak by an occlusion test. Because of sustained air leak, an addi-
tional EWS of 7-mm thickness was inserted into the left B3
segmental bronchi, resulting in termination of the air leaks. After
conﬁrming full expansion of the left lung during clamping the tube,
pleurodesis was performed with talc. Although air leak diminished,
dyspnea and high fever developed. The chest X-ray image on the
day 7 showed new consolidations in the left S3 and S5, suggesting
diminished lung volume and obstructive pneumonia (Fig. 3). High
fever and dyspnea resolved by antibiotics and the removal of the
EWS in the left B5. The drainage tube was removed on the day 14.
He was discharged on the 48th hospital day with support by 3 L/
min oxygen.Fig. 1. CT images before and after insertion of EWSs Upper, the left lung was collapsed
by the 2nd episode of pneumothorax. The bullous lesions are indicated by arrowheads.
Middle, full expansion of the left lung under the clamp of the chest tube was attained
by endoscopic occlusion of bronchopleural ﬁstula by endobronchial Watanabe spigots
(EWS). Lower, image showing an EWS in the left B3 (arrow).Discussion
Pneumothorax is a rare complication of cancer chemotherapy,
and it has been reported during the treatment of different types of
cancer and with various drugs [1e6]. Lai et al. reported that 18 out
of 5567 lung cancer patients (0.32%) experienced a pneumothorax
but only two out of these 18 patients developed pneumothorax
after chemotherapy (0.036%) [7]. Even in these two patients, it is
unclear whether chemotherapy triggered pneumothorax. Pneu-
mothorax was reported sporadically during treatment of lung
cancer with an EGFR-TKI, whereas it was not reported with
amrubicin [8e10]. In our patient, pneumothorax had not occurred
during an approximate 7-year history of chemotherapy that
included GEF alone, AMR alone and combination of GEF with
various cytotoxic drugs such as pemetrexed, gemcitabine, doce-
taxel and nab-paclitaxel. Only the speciﬁc combination of GEF and
AMR appears to have triggered pneumothorax. In addition, both
episodes of pneumothorax occurred on the 3rd day of GEF þ AMR
treatment, suggesting a causative relationship between this com-
bination of chemotherapeutic agents and pneumothorax. Several
authors reported chemotherapy-induced pneumothorax when a
dramatic responsewas inducedwith or without cavitation [6,11,12],
but this was not the case with our patient. Although chest CT
revealed bilateral extensive lung metastasis and multiple bullous
lesions (Fig. 1), the precise mechanism of pneumothorax by
GEF þ AMR in our patient is not clear.
Occlusion of the bronchopleural ﬁstula by transbronchial
insertion of EWS is reportedly effective for persistent air leaks in
pneumothorax in patients with poor respiratory reserve [13,14].
EWS was effective in our patient, resulting in termination of air
leaks and full expansion of the left lung, although transient pneu-
monia developed and dyspnea deteriorated. This report may
further the understanding of pneumothorax triggered by cancer
chemotherapy and contribute to its treatment in patients with se-
vere respiratory conditions.Fig. 3. Chest X-ray images after the insertion of the second EWS New consolidations
were observed in the left S3 and S5 on the day 7. The consolidation in the left S3 and S5
were decreased in size by antibiotics and the removal of the EWS in the left B5.
Dyspnea was resolved and high fever disappeared.
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